News

As reported in this week’s Nature Medicine, scientists based at the Cancer Research UK Man­chester Institute, Manchester, UK (CRUK MI), demonstrated that genetic patterns found in blood-borne cancer

Rexista is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.  The submission is

The candidate vaccine is a non-live, recombinant vaccine to help prevent shingles and its complications. The phase III clinical trial programme showed that by reducing the incidence of

The US healthcare firm said there can be no assurance any transaction will be signed from the preliminary negotiations. It also noted that further comments regarding the discussions

Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). The phase III programme includes two studies assessing the safety and efficacy of daprodustat compared to recombinant human erythropoietin.

This is the second and final study agreed with the U.S. Food and Drug Administration (FDA) to support the registration of liquid-frozen IMVAMUNE. The first study, a lot

The grant will fund a new clinical trial for Severe Combined Immunodeficiency caused by adenosine deaminase deficiency, commonly known as ADA-SCID or “bubble baby” disease. ADA-SCID is a

The requests raised by the FDA pertain only to Chemistry, Manufacturing and Controls (CMC). As the CRL did not cite efficacy or safety issues, Green Cross believes that

ORI Healthcare Fund (ORI Fund) led the Series C financing with participation by Shenzhen Hepalink Pharmaceutical (Hepalink). Existing shareholders Wellcome Trust, Bill & Melinda Gates Foundation, Malin Corporation,